Phospho-GATA3 (S308) Antibody

What is the biological significance of GATA3 phosphorylation at Ser308?

GATA3 phosphorylation at Ser308 serves multiple critical biological functions:

• In T-cells: Phosphorylation at Ser308 (along with Thr315 and Ser316) induces dissociation of histone deacetylase Hdac2 from the Gata3/Chd4 repressive complex in Th2 cells, leading to derepression of Tbx21 and Ifng expression . This modification allows certain memory Th2 cells to produce IFNγ in addition to Th2 cytokines.

• In breast cancer: Phosphorylation of GATA3 at Ser308 has been utilized as a marker of proteasomal turnover in ER-positive breast cancer cells . This phosphorylation creates a consensus binding site for 14-3-3τ, which can then interact with phospho-GATA3 .

• Evolutionary conservation: The Ser308 residue is highly conserved from drosophila to human, suggesting its fundamental importance in GATA3 function across species .

Which kinase is responsible for phosphorylating GATA3 at Ser308?

Akt1 (protein kinase B) has been conclusively identified as a key kinase responsible for GATA3 phosphorylation at Ser308. Multiple lines of evidence support this finding:

• In-gel kinase assays detected GATA3-specific kinase activity at approximately 55 kDa, which was identified as Akt1 through LC-MS/MS analysis .

• Co-immunoprecipitation experiments confirmed physical association between GATA3 and Akt1 .

• GATA3 phosphorylation levels increased in cells transfected with constitutively active Akt1 (myr-Akt1) and decreased in cells transfected with dominant-negative Akt1 (K179M) .

• The levels of Akt1 phosphorylation at Thr308 correlate with GATA3 phosphorylation status in memory Th2 cells .

• In vitro kinase assays showed that purified recombinant GATA3 could be phosphorylated by immunopurified Akt1, with this phosphorylation inhibited by Akt inhibitors in a dose-dependent manner .

What are the common applications for Phospho-GATA3 (S308) antibodies in research?

Phospho-GATA3 (S308) antibodies serve multiple research applications:

These antibodies have been validated for detection of phospho-GATA3 (S308) in human and mouse samples, with applications ranging from basic protein detection to complex mechanistic studies of GATA3 function in T cells and breast cancer models .

How does phosphorylation of GATA3 at Ser308 regulate its interaction with chromatin-modifying complexes?

The phosphorylation of GATA3 at Ser308 (along with Thr315 and Ser316) specifically regulates its interaction with the NuRD (Nucleosome Remodeling and Deacetylase) complex through selective disruption of GATA3-Hdac2 binding:

• Molecular mechanism: The C-finger region of GATA3 is important for association with Hdac2, a component of the NuRD complex. Phosphorylation in this region (Ser308, Thr315, Ser316) results in selective dissociation of Hdac2 from the GATA3 complex while maintaining interaction with Chd4 (another NuRD component) and p300 (a histone acetyltransferase) .

• Experimental evidence: Point mutants of GATA3 in which the Ser/Thr residues were substituted to phosphate-mimic Asp (Gata3 S/T-3D) showed impaired association with Hdac2 while preserving binding to Chd4 and p300 .

• Functional impact: Immunoprecipitation with anti-phospho-GATA3 antibody showed preserved Chd4 association but strikingly decreased Hdac2 association, confirming that phosphorylation selectively disrupts GATA3-Hdac2 interaction .

• Quantitative assessment: Two-step affinity purification demonstrated that Hdac2-associating GATA3 had substantially lower phosphorylation levels compared to total GATA3, indicating that phosphorylation and Hdac2 binding are mutually exclusive states .

This selective dissociation of Hdac2 from the GATA3/Chd4 complex upon phosphorylation provides a molecular switch that converts GATA3 from a repressor to an activator of specific target genes, particularly Tbx21 and Ifng .

What is the relationship between GATA3 S308 phosphorylation and 14-3-3τ interaction in breast cancer?

The relationship between GATA3 S308 phosphorylation and 14-3-3τ interaction in breast cancer represents a critical regulatory mechanism:

• Binding mechanism: 14-3-3τ binds its partners through highly conserved phosphoserine binding motifs. AKT-mediated phosphorylation of GATA3 at Ser308 creates a consensus binding site for 14-3-3τ .

• Experimental demonstration: GST-pulldown assays showed that GST-14-3-3τ was able to bind and pull down S308-phosphorylated GATA3, with peak interaction occurring 4 hours after treatment with SC-79, an AKT activator. This confirms direct binding between 14-3-3τ and phospho-GATA3 (S308) .

• Functional consequences: The 14-3-3τ-GATA3 interaction in breast cancer cells leads to:

  • Derepression of ERα36, a variant of the estrogen receptor

  • Altered estrogen receptor signaling

  • Changes in transcriptional programs

• Clinical relevance: This interaction appears to play a role in estrogen receptor loss in breast cancer, potentially contributing to the development of more aggressive phenotypes or resistance to endocrine therapies .

This phosphorylation-dependent interaction provides insight into how post-translational modifications of GATA3 can influence hormone receptor signaling and potentially impact breast cancer progression and treatment response .

How does Akt1-mediated GATA3 phosphorylation influence T-cell differentiation and cytokine production?

Akt1-mediated GATA3 phosphorylation serves as a molecular switch controlling T-cell differentiation and cytokine production through a complex regulatory mechanism:

• Effect on Th2/Th1 balance: While GATA3 typically promotes Th2 differentiation and represses Th1 cytokines, phosphorylation at Ser308, Thr315, and Ser316 allows memory Th2 cells to produce the Th1 cytokine IFNγ without losing their Th2 identity .

• Molecular mechanism: Phosphorylation by Akt1 induces dissociation of Hdac2 from the GATA3/Chd4 repressive complex, leading to derepression of Tbx21 (encoding T-bet, the master regulator of Th1 differentiation) and Ifng (encoding IFNγ) .

• Evidence from memory Th2 cells:

  • IFNγ-producing memory Th2 cells show higher levels of GATA3 phosphorylation compared to non-producing cells, with a higher ratio of phosphorylated GATA3 to total GATA3 .

  • These cells display higher phosphorylation status of Akt1 at Thr308 .

  • Memory Th2 cells with higher GATA3 phosphorylation show higher T-bet expression .

  • Akt inhibitor treatment specifically decreased IFNγ production (but not IL-4) from memory Th2 cells, confirming Akt's role in regulating IFNγ production .

• Clinical relevance: This mechanism may explain the phenotypic plasticity of memory T cells and their ability to adapt to different pathogenic challenges by modulating cytokine production without complete reprogramming .

This phosphorylation-dependent regulation highlights how post-translational modifications can fine-tune transcription factor activity to allow phenotypic flexibility within established cell lineages .

How should researchers optimize immunohistochemistry protocols for phospho-GATA3 (S308) detection in FFPE tissues?

Optimizing immunohistochemistry (IHC) protocols for phospho-GATA3 (S308) detection in formalin-fixed paraffin-embedded (FFPE) tissues requires careful attention to several critical parameters:

Recommended Protocol Optimization:

• Antibody selection and validation:

  • Use antibodies specifically validated for IHC in FFPE samples

  • Confirm specificity using positive controls (e.g., tissues known to express phospho-GATA3) and negative controls (e.g., tissues treated with phosphatase)

• Antigen retrieval optimization:

  • Test both heat-induced epitope retrieval methods:

    • Citrate buffer (pH 6.0)

    • EDTA buffer (pH 9.0)

  • Optimize retrieval time (typically 15-30 minutes)

  • Phospho-epitopes may be particularly sensitive to retrieval conditions

• Antibody dilution optimization:

  • Start with the manufacturer's recommended range (typically 1:50-1:200)

  • Perform titration experiments to determine optimal concentration

  • Consider signal-to-noise ratio when selecting final dilution

• Signal detection system:

  • Consider using amplification systems (e.g., tyramide signal amplification) for detecting low abundance phospho-epitopes

  • When used for breast cancer samples, 3,3'-diaminobenzidine (DAB) provides good contrast

• Counterstaining and controls:

  • Use hematoxylin counterstaining to provide context for cellular localization

  • Include phosphatase-treated controls to confirm phospho-specificity

  • Consider dual staining with total GATA3 antibody to assess phosphorylation ratio

Validation metrics: When validating phospho-GATA3 (S308) antibody for IHC, researchers have achieved sensitivity of 90% and specificity of 94% in breast cancer tissue microarrays containing luminal A/B tumors . This level of performance can serve as a benchmark for protocol optimization.

What are the critical considerations for using phospho-GATA3 (S308) antibodies in Western blot applications?

When using phospho-GATA3 (S308) antibodies in Western blot applications, researchers should address several critical considerations to ensure reliable and interpretable results:

Sample Preparation:

• Preserve phosphorylation status by including phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers

• Quick sample processing on ice and immediate denaturation in sample buffer containing SDS

• Consider enriching phosphoproteins using phospho-protein enrichment kits for low-abundance samples

Technical Parameters:

• Recommended antibody dilutions: 1:500-1:5000, with optimization required for each experimental system

• Blocking: Use 5% BSA in TBST rather than milk (milk contains casein phosphatases that may reduce signal)

• Use PVDF membranes (0.45 μm) for optimal protein binding and signal detection

• Include positive controls (e.g., cells treated with AKT activators like SC-79)

Controls and Validation:

• Essential controls include:

  • Phosphatase-treated lysates to confirm phospho-specificity

  • Total GATA3 antibody on parallel blots to assess phosphorylation ratio

  • Positive controls from cells with known GATA3 phosphorylation status (e.g., D10G4.1 cells)

Interpretation Considerations:

• GATA3 phosphorylation may be dynamic, with peak phosphorylation occurring at specific time points after stimulation

• In GST-pulldown assays, peak interaction between 14-3-3τ and phospho-GATA3 (S308) was observed 4 hours after AKT activation

• Phosphorylation status should be quantified as a ratio to total GATA3 protein levels, as absolute phospho-GATA3 levels may be misleading if total GATA3 expression varies

Troubleshooting Common Issues:

• Weak signals may require signal enhancement systems or increased antibody concentration

• High background may necessitate more stringent washing or reduced antibody concentration

• Multiple bands may represent different GATA3 isoforms or proteolytic fragments

What experimental approaches can be used to study the functional consequences of GATA3 S308 phosphorylation?

To comprehensively study the functional consequences of GATA3 S308 phosphorylation, researchers can employ multiple complementary experimental approaches:

1. Phosphomimetic and Phospho-dead Mutants:

• Generate GATA3 mutants where S308 (along with T315 and S316) is replaced with:

  • Alanine (S308A) - phospho-dead mutant that cannot be phosphorylated

  • Aspartic acid (S308D) - phosphomimetic mutant that mimics constitutive phosphorylation

• Compare these mutants in functional assays to determine the impact of phosphorylation state

• Express these mutants in GATA3-negative or GATA3-knockdown cells to assess rescue capabilities

2. Protein-Protein Interaction Studies:

• Co-immunoprecipitation assays using phospho-specific antibodies to identify interacting partners of phosphorylated GATA3

• GST-pulldown assays with recombinant proteins to confirm direct interactions

• Proximity ligation assays (PLA) to visualize and quantify protein interactions in situ

• Two-step affinity purification to isolate specific complexes containing phosphorylated GATA3

3. Chromatin Association and Transcriptional Activity:

• Chromatin immunoprecipitation (ChIP) with phospho-GATA3 antibodies to identify genomic binding sites

• ChIP-seq to map genome-wide binding patterns of phosphorylated vs. non-phosphorylated GATA3

• Luciferase reporter assays to assess transcriptional activity of phospho-mimetic vs. phospho-dead GATA3 on target promoters

• RNA-seq to identify genes differentially regulated by phosphorylation status

4. Functional Cellular Assays:

• In T cells: Cytokine production assays (ELISA, flow cytometry) to assess how phosphorylation affects T-helper cell differentiation and function

• In breast cancer cells: Proliferation, migration, and invasion assays to determine impact on oncogenic properties

• Response to treatment (e.g., hormone therapy in breast cancer)

5. Pharmacological Manipulation:

• Treat cells with Akt inhibitors to block phosphorylation and assess functional consequences

• Use SC-79 (an Akt activator) to increase phosphorylation

• Employ proteasome inhibitors (e.g., bortezomib) to study the relationship between phosphorylation and protein stability

6. In vivo Studies:

• Generate knock-in mouse models expressing phospho-mimetic or phospho-dead GATA3

• Assess impact on T-cell development, differentiation, and function in vivo

• Evaluate tumor growth and metastasis in breast cancer models

When designing these experiments, it's important to consider that GATA3 phosphorylation may have context-dependent effects, varying between cell types (T cells vs. breast epithelial cells) and physiological states (normal development vs. cancer).

How can researchers distinguish between phosphorylated and non-phosphorylated GATA3 in experimental systems?

Researchers can employ several complementary approaches to reliably distinguish between phosphorylated and non-phosphorylated GATA3:

Antibody-Based Detection Methods:

• Phospho-specific vs. total GATA3 antibodies:

  • Use phospho-GATA3 (S308) antibodies alongside total GATA3 antibodies on parallel samples

  • Calculate phosphorylation ratio by normalizing phospho-signal to total GATA3

  • This approach has been successfully employed in various studies

• Mobility shift detection:

  • Phosphorylated proteins often migrate differently in SDS-PAGE

  • Use high-resolution gels (e.g., 8-10% acrylamide with low cross-linking) to detect subtle shifts

  • Lambda phosphatase treatment of parallel samples can confirm phosphorylation-dependent shifts

• Two-dimensional gel electrophoresis:

  • Separate proteins first by isoelectric point (affected by phosphorylation) then by molecular weight

  • Phosphorylated GATA3 will appear at a more acidic pH compared to non-phosphorylated form

Enrichment and Fractionation Techniques:

• Phosphoprotein enrichment:

  • Use phosphoprotein enrichment columns prior to detection

  • This can increase sensitivity for detecting low-abundance phosphorylated forms

• Subcellular fractionation:

  • Phosphorylated GATA3 (S308) has been shown to have distinct subcellular localization

  • Nuclear fractions showed higher levels of phospho-S308 GATA3 compared to cytosolic fractions after bortezomib treatment

  • Use histone H3 as a control for nuclear fraction purity

Mass Spectrometry-Based Approaches:

• LC-MS/MS analysis:

  • Identifies exact phosphorylation sites and can be quantitative

  • Has successfully detected phosphorylation at Ser308, Thr315, and Ser316 in the linker region and C-finger motif of GATA3

  • Can determine phosphorylation stoichiometry (percentage of protein modified)

Functional Validation:

• Interaction partners as surrogate markers:

  • Phosphorylated GATA3 (S308) specifically interacts with 14-3-3τ

  • Co-immunoprecipitation or proximity ligation assays with 14-3-3τ can serve as functional validation of phosphorylation status

• Hdac2 association:

  • Phosphorylated GATA3 shows decreased association with Hdac2

  • Measuring Hdac2 association can serve as indirect confirmation of phosphorylation status

What are the implications of GATA3 S308 phosphorylation in breast cancer progression and potential therapeutic approaches?

GATA3 S308 phosphorylation has significant implications for breast cancer biology and therapeutic strategies:

Prognostic Significance:

• The GATA3 X308_Splice mutation, which eliminates the S308 phosphorylation site, is a hotspot mutation in breast cancer that correlates with significantly better patient outcomes .

• This mutation produces a shorter "neoGATA3" protein lacking residues 308-444 (including the second zinc finger) and containing a novel 44aa C-terminal sequence .

• The absence of S308 in neoGATA3 prevents phosphorylation that normally signals to the proteasome, potentially affecting protein stability and function .

Molecular Mechanisms:

• Estrogen and Progesterone Receptor Signaling:

  • Phospho-GATA3 (S308) impacts estrogen receptor (ER) signaling through complex mechanisms involving 14-3-3τ .

  • The 14-3-3τ-GATA3 interaction leads to ERα36 induction, potentially contributing to estrogen receptor loss .

  • These interactions can blunt hormone receptor programs without completely abrogating them .

• Context-Dependent Growth Effects:

  • neoGATA3-expressing cells (lacking S308) show differential growth effects depending on hormonal context:

    • Proliferative advantage when both estrogen and progesterone levels are high (premenopausal state)

    • Growth disadvantage when estrogen predominates (postmenopausal state)

  • This suggests stage-dependent oncogenic effects of GATA3 mutations affecting S308 phosphorylation.

• Immune Microenvironment:

  • neoGATA3 tumors show significant decreases in immune cell signatures, including:

    • T cell signatures (p=0.002)

    • CD8+ T cell signatures (p=8.12e-06)

    • NK cell signatures (p=8.1e-05)

    • Cytotoxic lymphocyte signatures (p=2.9e-04)

  • Expression of immune checkpoint proteins PD-1 (p=0.005) and PD-L1 (p=0.033) is lower in neoGATA3 tumors .

Therapeutic Implications:

• Hormone Therapy Considerations:

  • GATA3 phosphorylation status may influence response to hormone therapies in ER-positive breast cancer.

  • The differential effects based on hormonal context suggest potential for personalized therapeutic approaches based on menopausal status .

• AKT Pathway Targeting:

  • As Akt1 is a key kinase for GATA3 S308 phosphorylation , AKT inhibitors might affect GATA3 function.

  • Combining AKT inhibitors with hormone therapies could potentially synergize by affecting multiple aspects of ER signaling.

• Immunotherapy Considerations:

  • The reduced immune cell infiltration in tumors with altered GATA3 S308 (neoGATA3) suggests potential resistance to immunotherapies .

  • Strategies to enhance immune infiltration might be particularly important in these tumors.

• Biomarker Potential:

  • Phospho-GATA3 (S308) status could serve as a biomarker for:

    • Prognosis in breast cancer

    • Prediction of response to hormone therapies

    • Selection of patients for combined therapeutic approaches